20th International Workshop on Co‑morbidities and Adverse Drug Reactions in HIV

76 Pages·2017·0.81 MB·English

Abstracts presented at the
20th International Workshop on Co‑morbidities
and Adverse Drug Reactions in HIV
New York, USA, 13–14 October 2018
cover page.indd 1 04/10/2018 15:47:09
ORGANIZING COMMITTEE
Chairs for 2018
Jacqueline Capeau Faculty of Medicine Saint Antoine, INSERM, Paris, France
Donald Kotler Columbia University, New York, NY, USA
Morrie Schambelan University of California at San Francisco, CA, USA
Todd Brown Johns Hopkins University, Baltimore, MD, USA
Andrew Carr St Vincent’s Hospital, Sydney, Australia
Judith Currier University of California, Los Angeles, CA, USA
Stefan Mauss Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Peter Reiss Academic Medical Center, Amsterdam, the Netherlands
SCIENTIFIC COMMITTEE
Michael Dubé University of Southern California, Los Angeles, CA, USA
Julian Falutz Immune Deficiency Treatment Center, Montreal General Hospital, Montreal, Canada
Steve Grinspoon Massachusetts General Hospital, Boston, MA, USA
Carl Grunfeld University of California Medical Center, San Francisco, CA, USA
Giovanni Guaraldi University of Modena, Modena, Italy
Colleen Hadigan National Institute of Allergy and Infectious Diseases, National Institutes of Health,
Bethesda, MD, USA
Donald Kotler Columbia University, New York, NY, USA
Jordan Lake The University of Texas, Houston, TX, USA
Jules Levin The National AIDS Treatment Advocacy Project, New York, NY, USA
Jens Lundgren University of Copenhagen, Hvidovre, Denmark
Paddy Mallon University College Dublin, Dublin, Ireland
Esteban Martínez IDIPAPS - Hospital Clinic, University of Barcelona, Barcelona, Spain
Graeme Moyle Chelsea and Westminster Hospital, London, UK
Kathleen Mulligan University of California at San Francisco, CA, USA
Pablo Tebas University of Pennsylvania, Philadelphia, PA, USA
Sharon Walmsley University Health Network, Toronto, Canada
Kevin Yarasheski Washington University, St Louis, MO, USA
PLENARY SPEAKERS
Siddhartha Jaiswal Stanford University, Stanford, CA, USA
Peter Libby Harvard Medical School, Boston, MA, USA
Alison Morris University of Pittsburgh, Pittsburgh, PA, USA
Eugene Sobngwi Yaoundé Central Hospital, Cameroon
Serena Spudich Yale School of Medicine, New Haven, CT, USA
ORGANIZING SECRETARIAT
International Medical Press Admiral House
76–78 Old Street
London, EC1V 9AZ, UK
Tel: [phone]
Fax: [phone]
www.intmedpress.com/comorbidities
[email protected]
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV v
Prelims_2018.indd 5 21/09/2018 14:32:08
ABSTRACT CONTENTS
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
ORAL PRESENTATIONS
Session 1
A3 Plasma desmosine and isodesmosine and lung function among people O01
with or at risk of HIV infection
J Sun
A4 Alterations in oral and gut microbiota in HIV-infected individuals related O02
to pulmonary function
L Yang
A5 Analysis of different lung cancer screening scenarios in the French O03
Hospital Database on HIV (ANRS CO4-FHDH cohort): number of subjects
to screen to diagnose one cancer and proportion of cancers diagnosed
A Makinson
Session 2
A6 HIV-1 transgene expression in mice: a model for non-drug-mediated O04
alterations in metabolism, adiposity and bone homeostasis in patients
J Villarroya
A7 Early changes in bone turnover and immune activation markers and O05
subsequent BMD loss in the SECOND-LINE Study
GE Mwasakifwa
A8 Changes in bone mineral density over 3 years with zoledronic acid or O06
TDF switching in adults on tenofovir DF with low bone mineral density
A Carr
Session 3
A9 Integrated versus referred management of cardiovascular disease (CVD) O07
risk factors for HIV-positive patients on antiretroviral therapy
in Swaziland
P Bongomin
A10 Coronary artery calcium (CAC) scores among long-term virologically O08
suppressed non-diabetic HIV-infected elderly Asians
WM Han
A11 Liver fibrosis among HIV-infected persons in rural Uganda in the era O09
of ART
C Wekesa
A12 Substantial gender differences in longitudinal arterial stiffness in O10
children on ART
S Innes
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xiii
Prelims_2018.indd 13 21/09/2018 14:32:08
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Session 4
A13 Partial normalization of some biomarkers of inflammation in highly O11
ART-adherent, virally suppressed men with HIV infection
NI Wada
A14 Valganciclovir reduces an immune activation pathway that strongly O12
predicts morbidity and mortality in treated HIV infection
PW Hunt
A15 Randomized double-blind placebo-controlled trial of vorapaxar for O13
HIV-associated inflammation and coagulopathy – the ADVICE study
S Kent
Session 5
A16 Predictive performance of cardiovascular disease risk equations in O14
people living with HIV
RA van Zoest
A17 Transgender women have novel circulating cardiovascular and O15
inflammatory biomarker profiles that vary with hormone use and
HIV serostatus and differ from MSM controls
P Debroy
A18 Novel markers of cardiovascular risk in people living with HIV O16
JM Trevillyan
Session 6
A19 HIV-negative men who have sex with men have lower CD4 to CD8 ratios O17
driven by higher absolute CD8 T-lymphocyte counts compared to
HIV-negative heterosexual men
SO Verboeket
A20 Inflammatory biomarkers, adipokines and longitudinal changes in gait O18
speed and fatigue in men with or at risk for HIV infection
J Sun
A21 HIV serostatus and higher IL-6 and D-dimer levels are associated with O19
lower small HDL particle number in the Multicenter AIDS Cohort Study
S Sarkar
A22 The association of lung function with HIV-related quality of life and O20
health-care utilization in a high-risk cohort
S Raju
Session 7
A24 Potential indicators of fibrosis progression and regression following O21
HCV treatment in patients with and without HIV
J Balmaceda
A25 Increased prevalence of hepatic steatosis in young adults with O22
life-long HIV infection
JA Aepfelbacher
A26 HIV-infected individuals using integrase inhibitors are at high risk of O23
weight gain
DR Bakal
xiv Programme & Abstracts
Prelims_2018.indd 14 21/09/2018 14:32:08
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
A27 ART initiation with integrase inhibitors is associated with greater O24
weight gain than with PI- or NNRTI-based ART in the US and Canada
JE Lake
POSTER PRESENTATIONS
Adipocyte biology, insulin resistance & lipid metabolism
A31 Favourable phenotype of LDL particles in subjects with high P01
cardiovascular risk switching from a ritonavir-boosted protease inhibitor
to dolutegravir. Results of the NEAT 022 study
M Saumoy Linares
A32 Phenotypic analysis of CD4+ and CD8+ T-cell subsets in adipose tissue P02
of people living with HIV reveals increased CD69 expression with
progressive insulin resistance
CN Wanjalla
Aging, frailty, disability & immune senescence
A33 Physical functioning among patients ageing with HIV versus P03
HIV-uninfected: feasibility of using the Short Performance Physical
Battery in clinical care of people living with HIV aged 50 or older
HM Crane
A34 The clinical heterogeneity of PLWH switching to dual therapy is levelled P04
in 2-year follow-up in a real-life cohort
G Guaraldi
A35 Barriers to health-promoting behaviour in people living with HIV: P05
implications for comorbidity development
JD Perazzo
A36 Determinants and trends in daily step count for older adults living with P06
and without HIV participating in a monitored exercise programme
AC Stabell
A37 Impact of ageing and duration of cART on self-reported health outcomes P07
in people living with HIV
S Walmsley
Body composition
A39 Weight misperception is common among people living with HIV P08
P Debroy
A40 Tesamorelin (EGRIFTA) formulations: bioequivalence in healthy subjects P09
M De Chantal
A41 Dietary protein intake and obesity, but not physical activity, impact gut P10
microbial composition in older adults living with HIV
AL Willig
Bone metabolism & toxicities
A43 Central obesity is associated with low bone mineral density at femoral P11
neck in Chinese men living with HIV
G Lui
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xv
Prelims_2018.indd 15 21/09/2018 14:32:08
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Cardiovascular disease
A45 The antiretroviral drugs dolutegravir, maraviroc and ritonavir-boosted P12
atazanavir could affect inflammation and insulin sensitivity in human
coronary endothelial cells through different signalling pathways
J Capeau
A46 Increasing utilization of direct oral anticoagulants (DOACs) and drug P13
interactions in people living with HIV (PLWH) on antiretroviral
therapy (ART): data from the DC Cohort
C Hadigan
A47 Subclinical cardiovascular function in abacavir-treated HIV patients P14
CA Martinez
A48 Switching tenofovir disoproxil fumarate to tenofovir alafenamide P15
not only bone and kidney
S Mauss
A49 Changes in dynamic platelet function when switching from ABC/3TC to P16
TAF/FTC: GS-US-311-1717 Platelet Substudy
PMC McGettrick
A50 Evaluation of lipid levels and cardiovascular risk in HIV-infected patients P17
24 weeks after being switched from a tenofovir disoproxil fumarate to a
tenofovir alafenamide containing regimen in a clinic in Puerto Rico
I Melendez-Rivera
A51 Associations of antiretroviral therapy (ART) with lipid measurements P18
among people with HIV (PWH)
CA Sabin
A52 Evaluation of low-density lipoprotein cholesterol (LDL-C) in HIV-infected P19
men using the traditional Friedewald and the novel Martin-Hopkins
LDL-C equations
EE Schneider
A53 Ankle-brachial index and pulse-wave velocity are altered in people with P20
HIV but are not predictive of future cardiovascular disease
JM Trevillyan
Clinical management of ADRs
A55 Adverse event data from studies of initial antiretroviral therapy are P21
under-reported and their reporting is biased
A Carr
A57 HLA-B*57:01 allele prevalence in seropositive HIV-naive population P22
in Colombia
E Martínez
Liver disease & hepatotoxicity
A59 Hepatic steatosis is common in both lean and obese adults with HIV P23
infection and associated with divergent immuno-metabolic profiles
JE Lake
A60 Testosterone in men with chronic hepatitis C infection with and P24
without HIV: response to hepatitis C viral clearance
C Hadigan
xvi Programme & Abstracts
Prelims_2018.indd 16 21/09/2018 14:32:09
PAGE TITLE AND PRESENTING AUTHOR ABSTRACT
Other co-morbidities (cancer, neurocognitive disorders & renal toxicities)
A61 Prevalence of renal toxicity among people living with HIV (PLWHIV) using P25
antiretroviral treatment (ART) in Togo
K Aho
A62 Design and implementation of a venous thromboembolism (VTE) P26
adjudication system in the CFAR Network of Integrated Systems
(CNICS) cohort
HM Crane
A63 Associations of non-antiretroviral concomitant medications with cognitive P27
function of people living with HIV (PLWH) and HIV-negative controls
D De Francesco
A64 Sitagliptin for reducing inflammation and immune activation in HIV: P28
ACTG 5346 – results of monocyte and lymphocyte activation markers
and metabolic variables from a randomized, double-blind,
placebo-controlled trial
MP Dubé
A65 Renal stones: a drug-induced or metabolic complication of HIV? P29
C Isnard Bagnis
A66 Benefit of an annual screening of comorbidities for people living with HIV, P30
in a day-care hospital
M Michaud
A67 The rhesus macaque as a preclinical model for HIV comorbidities P31
CT Roberts
A68 Can HIV-associated neurocognitive disorder (HAND) be treated with P32
computerized cognitive training? Evidence from a systematic review
DE Vance
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV xvii
Prelims_2018.indd 17 21/09/2018 14:32:09

ORAL PRESENTATIONS
Orals.indd 1 20/09/2018 15:48:12
Orals.indd 2 20/09/2018 15:48:12